Essential Partners’s Halozyme HALO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$3.31K Hold
30
– – ﹤0.01% 1706
2026
Q2
$2.35K Sell
30
-16
-35% -$1.09K ﹤0.01% 1910
2026
Q1
$2.97K Sell
46
-707
-94% -$49.8K ﹤0.01% 1828
2025
Q4
$50.7K Sell
753
-162
-18% -$10.9K 0.02% 604
2025
Q3
$67.1K Buy
915
+912
+30,400% +$60.6K 0.02% 528
2025
Q2
$156 Buy
+3
New +$171 ﹤0.01% 1998

Other funds holding HALO

Essential Partners's HALO Position: Q3 2026 in Review

Essential Partners held its Halozyme (HALO) position steady in Q3 2026 at 30 shares worth $3.31K. The position accounts for ﹤0.01% of the portfolio, ranked #1706.

Essential Partners first reported a position in HALO in Q2 2025 and has held it in 6 quarters since. The position peaked at $67.1K in Q3 2025. 161 funds tracked by Wall St. Rank hold HALO as of Q3 2026.

  • Essential Partners held 30 shares of Halozyme worth $3.31K as of Q3 2026.
  • Essential Partners left its Halozyme share count unchanged in Q3 2026.
  • Halozyme made up ﹤0.01% of Essential Partners's portfolio in Q3 2026, its #1706 holding.
  • Essential Partners first reported a position in Halozyme in Q2 2025 and has held it in 6 quarters since.
  • Essential Partners's Halozyme position peaked at $67.1K in Q3 2025.
  • 161 funds tracked by Wall St. Rank held Halozyme as of Q3 2026.

Based on Essential Partners's 13F filing for Q3 2026, filed 14 Oct 2026.